SCHEMBL2174333

SCHEMBL2174333

CC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(C=C3SC(=O)N(C(C)C4CCCCC4)C3=O)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.46
ALDH1A1 P00352 6/20 0.46
GAA P10253 3/20 0.46
GFER P55789 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HSD17B10 Q99714 1/20 0.44
MEN1 O00255 7/20 0.42
MAPT P10636 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
POLB P06746 4/20 0.41
MCL1 Q07820 3/20 0.41
USP2 O75604 1/20 0.41
NPC1 O15118 1/20 0.41
AURKA O14965 1/20 0.41
MTOR P42345 1/20 0.41
MAPK1 P28482 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2785877 0.91 MEN1 (0.43) KMT2AALDH1A1GAAL3MBTL1MEN1
SCHEMBL2785875 0.91 MEN1 (0.43) KMT2AALDH1A1GAAL3MBTL1MEN1
SCHEMBL2785880 0.91 MEN1 (0.43) KMT2AALDH1A1GAAL3MBTL1MEN1
SCHEMBL2785873 0.91 DHODH (0.46) KMT2AALDH1A1GAAHSD17B10MEN1
SCHEMBL2174414 0.91 DHODH (0.46) KMT2AALDH1A1GAAHSD17B10MEN1
SCHEMBL2172048 0.89 ALDH1A1 (0.47) KMT2AALDH1A1HSD17B10MEN1MAPT
SCHEMBL2786293 0.89 ALDH1A1 (0.47) KMT2AALDH1A1HSD17B10MEN1MAPT
SCHEMBL2786112 0.88 AURKA (0.43) KMT2AALDH1A1MEN1MAPTSMN1; SMN2
SCHEMBL2172237 0.88 AURKA (0.43) KMT2AALDH1A1MEN1MAPTSMN1; SMN2
SCHEMBL1672882 0.88 BCL2 (0.45) KMT2AALDH1A1MEN1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2254576-B1 ANDROGEN RECEPTOR-ABLATIVE AGENTS UNIV OHIO STATE RES FOUND (US) 2013-08-28 EP claimed
US-7973062-B2 Androgen receptor-ablative agents THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2011-07-05 US claimed
EP-2254576-A1 ANDROGEN RECEPTOT-ABLATIVE AGENTS The Ohio State University Research Foundation (US) 2010-12-01 EP claimed
US-20090291992-A1 ANDROGEN RECEPTOR-ABLATIVE AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-11-26 US claimed
WO-2009105621-A1 ANDROGEN RECEPTOT-ABLATIVE AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-08-27 WO claimed
EP-2254576-B1 ANDROGEN RECEPTOR-ABLATIVE AGENTS UNIV OHIO STATE RES FOUND (US) 2013-08-28 EP disclosed
US-7973062-B2 Androgen receptor-ablative agents THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2011-07-05 US disclosed
US-20090291992-A1 ANDROGEN RECEPTOR-ABLATIVE AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291992-A1 ANDROGEN RECEPTOR-ABLATIVE AGENTS AR, ESRRB, KLK3 KMT2A 1669/4885ALDH1A1 96/4885GAA 2785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.